hotspot -WSS

hotspot

author：comprehensive 2025-10-01 21:34:00 - browse：74123

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

Wikipedia

WSS

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Shifting the focus from loneliness to social health

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Case highlights the risks of experimental stem cell therapy

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

entertainment

hotspot

hotspot

Psychedelics group wrestles with new pharma identity

FDA's Pazdur wants cancer trials to range beyond China alone

Virginia high school admissions case could be legal follow

Innovation in antibiotics is ailing. 'Brain drain' may kill it

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Walensky prepares to leave CDC — and Congress — behind

Addiction experts warn against a second 'war on drugs'

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Venture capitalist Bob Kocher on the state of digital health

leisure time

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Woman returns to dialysis after doctors remove transplanted pig kidney

Change Healthcare can notify patients about the breach, HHS says

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Wikipedia

focus

hotspot

knowledge